Source: Annual Congress 2010 - Quality management for lung cancer patients



Rating:

Share or cite this content

Citations should be made in the following way:
M. A. van der Drift, H. E. Karim-Kos, S. Siesling, H. J. M. Groen, E. de Vries, M. L. G. Janssen-Heijnen (Nijmegen, Rotterdam, Enschede, Groningen, Eindhoven, Netherlands). Time trends in treatment and survival of non-small cell lung cancer in The Netherlands. Eur Respir J 2010; 36: Suppl. 54, 286

Member's Comments

No comment yet.

Related content which might interest you: Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC) Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Does long treatment delay affect survival in metastatic non-small cell lung cancer Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Advanced non-small cell lung cancer (NSCLC): observation of chemotherapy in 5 European countries Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007 Epidemiological and clinical predictors of survival during the first year of the treatment in non-small cell lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Surveillance imaging and recurrence rates following surgery for non-small cell lung cancer (NSCLC). Source: Virtual Congress 2020 – Localised non-small cell lung cancer Year: 2020 Risk factor for survival in never-smokers non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series Year: 2010 Delays in the diagnosis and treatment of non-small cell lung cancer Source: Annual Congress 2010 - Quality management for lung cancer patients Year: 2010 10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient Source: Eur Respir J 2015; 46: 280-282 Year: 2015 Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 The 7-year results of the surgical treatment of non-small cell lung cancer (NSCLC) patients and the influence of neoadjuvant treatment Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007 Tumour metabolic-flow difference as a potential predictor of survival in non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Staging of lung cancer Year: 2010 Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002 One year survival differences of EGFR- and KRAS-mutated advanced non-small cell lung cancer (NSCLC) compared to the wildtype population Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Impacts of multi and specific co-morbidities on the survival of non-surgical non-small cell lung cancer Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Survival impact of surgery in the treatment of stage IIIB-IVA non-small cell lung cancer Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Effect of comorbidity on the prognosis of non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 385s Year: 2006